Advancis Pulsys platform gets second try
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Advancis is moving ahead with another Phase III trial of its Pulsys pulsatile formulation of amoxicillin, the firm says Nov. 3. After a pre-Phase III meeting with FDA to discuss the 600-patient trial, the firm says it is on track to submit a 505(b)(2) NDA for treatment of adults and adolescents with strep throat in "late 2006." The two-arm trial will compare a 10-day regimen of once-daily amoxicillin Pulsys to penicillin VK dosed four times daily. Advancis previously indicated that the new trial could be its last chance to prove the viability of the Pulsys technology. The amoxicillin formulation previously failed to show statistical non-inferiority to penicillin in two Phase III studies (1Pharmaceutical Approvals Monthly October 2005, p. 8)...
You may also be interested in...
Advancis’ Last Try For Pulsys Platform? New Phase III Trial To Start In November
Advancis is prepared to begin a new Phase III trial of its Pulsys pulsatile amoxicillin formulation in November in hopes of following through with its previously planned NDA
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.